Pilot clinical study to evaluate the safety and effectiveness of PrimCell autologous cell separator for stable refractory Vitiligo in children and adolescents

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073662

Enrollment

Unknown

Registered

2023-07-18

Start date

2023-07-20

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

test group :Transplantation of autologous normal cells with PrimCell autologous cell separator

control group:308 excimer light therapy

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: ? Age 6-18 years old; ? Clinical diagnosis: Vitiligo; ? Stable white spots for at least 1 year; ? No homomorphic reaction

Exclusion criteria

Exclusion criteria: ? Accompanied by severe systemic diseases; ? Scar constitution; ? Patients with bleeding tendencies; ? Patients and parents with high expectations for treatment outcomes; ? Other situations where the researcher deems it inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
White spot area; The situation of white spot discoloration;	—

Secondary

Measure	Time frame
discoloration mode;Color matching of discoloration skin;patient satisfaction;	—

Countries

China

Contacts

Public ContactDan Deng

Shanghai Children's Medical Center, affiliated to Shanghai Jiao Tong University School of Medicine

dengdan1234567@126.com+86 180 1852 7652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026